These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 29574075

  • 1. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
    Viney NJ, Yeang C, Yang X, Xia S, Witztum JL, Tsimikas S.
    J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI, Ezhov MV, Razova OA, Afanasieva MI, Utkina EA, Pokrovsky SN.
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [Abstract] [Full Text] [Related]

  • 3. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.
    Lancet; 2016 Nov 05; 388(10057):2239-2253. PubMed ID: 27665230
    [Abstract] [Full Text] [Related]

  • 4. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G.
    J Clin Lipidol; 2018 Nov 05; 12(1):130-136. PubMed ID: 29103916
    [Abstract] [Full Text] [Related]

  • 5. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.
    Circulation; 2017 Jan 24; 135(4):352-362. PubMed ID: 27986651
    [Abstract] [Full Text] [Related]

  • 6. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Morikawa N, Sakaue A, Toyomasu K, Yamamoto M, Fukumoto Y.
    J Atheroscler Thromb; 2021 Apr 01; 28(4):329-337. PubMed ID: 32624555
    [Abstract] [Full Text] [Related]

  • 7. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB, Brooks N, Tavori H, Minnier J, Duell B, Purnell JQ, Kaufman T, Wojcik C, Voros S, Fazio S, Shapiro MD.
    J Clin Lipidol; 2017 Apr 01; 11(3):667-673. PubMed ID: 28506388
    [Abstract] [Full Text] [Related]

  • 8. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
    Watts GF, Chan DC, Pang J, Ma L, Ying Q, Aggarwal S, Marcovina SM, Barrett PHR.
    Metabolism; 2020 Jun 01; 107():154221. PubMed ID: 32240727
    [Abstract] [Full Text] [Related]

  • 9. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 01; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 10. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJP.
    Circulation; 2018 Sep 25; 138(13):1304-1316. PubMed ID: 29735484
    [Abstract] [Full Text] [Related]

  • 11. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials.
    Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S.
    J Clin Lipidol; 2018 Sep 25; 12(1):122-129.e2. PubMed ID: 29174389
    [Abstract] [Full Text] [Related]

  • 12. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.
    Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, Tsimikas S.
    J Am Coll Cardiol; 2022 Mar 22; 79(11):1035-1046. PubMed ID: 35300814
    [Abstract] [Full Text] [Related]

  • 13. Effect of long-term physical activity on PCSK9, high- and low-density lipoprotein cholesterol, and lipoprotein(a) levels: a prospective observational trial.
    Sponder M, Campean IA, Dalos D, Emich M, Fritzer-Szekeres M, Litschauer B, Bergler-Klein J, Graf S, Strametz-Juranek J.
    Pol Arch Intern Med; 2017 Aug 09; 127(7-8):506-511. PubMed ID: 28607329
    [Abstract] [Full Text] [Related]

  • 14. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS.
    Circulation; 2013 Aug 27; 128(9):962-9. PubMed ID: 23884353
    [Abstract] [Full Text] [Related]

  • 15. PCSK9 Association With Lipoprotein(a).
    Tavori H, Christian D, Minnier J, Plubell D, Shapiro MD, Yeang C, Giunzioni I, Croyal M, Duell PB, Lambert G, Tsimikas S, Fazio S.
    Circ Res; 2016 Jun 24; 119(1):29-35. PubMed ID: 27121620
    [Abstract] [Full Text] [Related]

  • 16. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.
    Arch Med Res; 2012 Jan 24; 43(1):11-4. PubMed ID: 22300679
    [Abstract] [Full Text] [Related]

  • 17. 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering.
    Yeang C, Witztum JL, Tsimikas S.
    Curr Opin Lipidol; 2015 Jun 24; 26(3):169-78. PubMed ID: 25943842
    [Abstract] [Full Text] [Related]

  • 18. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.
    Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD.
    Eur J Prev Cardiol; 2021 Jul 23; 28(8):816-822. PubMed ID: 34298554
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
    Hopkins PN, Krempf M, Bruckert E, Donahue S, Yang F, Zhang Y, DiCioccio AT.
    J Clin Lipidol; 2019 Jul 23; 13(6):970-978. PubMed ID: 31767518
    [Abstract] [Full Text] [Related]

  • 20. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly.
    Croyal M, Blanchard V, Ouguerram K, Chétiveaux M, Cabioch L, Moyon T, Billon-Crossouard S, Aguesse A, Bernardeau K, Le May C, Flet L, Lambert G, Hadjadj S, Cariou B, Krempf M, Nobécourt-Dupuy E.
    Arterioscler Thromb Vasc Biol; 2020 Mar 23; 40(3):819-829. PubMed ID: 32078365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.